key: cord-0791901-b20e4i9s
authors: Gueguen, Lorraine; Loheac, Charlotte; Saidani, Nadia; Khatchatourian, Lydie
title: Membranous nephropathy following anti-Covid-19 mRNA vaccination.
date: 2021-08-20
journal: Kidney Int
DOI: 10.1016/j.kint.2021.08.006
sha: 02ceab5e2316d1e56a6146c9ad2e66f1d2cc2c93
doc_id: 791901
cord_uid: b20e4i9s

nan

A 76-year-old man with a past history of hypertension and UV-treated cutaneous mycosis fungoid, was vaccinated in January 2021 for SARS-CoV2 with Bnt162b2 and developed an antibody response. He had not had prior COVID-19 infection. He developed edema 4 days post-vaccination with a random spot urine protein-creatinine ratio (PCR) of 6.5 g/g, hypoalbuminemia (1.6 g/dL), hematuria, and normal serum creatinine (SCr, 0.86 mg/dl). His anti-phospholipase A2 receptor (PLA2R) autoantibody titer was found to be 1:800 (maximal dilution for this assay), supporting a diagnosis of membranous nephropathy (MN) 1 . As there were no other clinical data to suggest an alternative diagnosis a kidney biopsy was not performed. He was initially treated symptomatically, with dietary modification and renin-angiotensin system blockade, resulting in partial control of the nephrotic syndrome (body weight stabilized, serum albumin increased to 2.6 g/dL, urine PCR fell to 3 g/g, creatinine increased to 1.14 mg/dL, and the titer of anti-PLA2R did not change).

He was given the SARS-CoV2 mRNA-1273 vaccine for his second dose to maintain mRNA vaccination but avoid a second dose of Bnt162b2. Two days later his edema worsened, serum albumin fell to 2.2 g/dL, urine PCR increased to 3.8 g/g, and serum creatinine was stable at 1.15 mg/dL. At this time rituximab treatment was initiated and resulted in a partial remission at two months (Fig. 1) .

To our knowledge, this is the first case of MN occurring after anti-Covid-19 mRNA vaccination. A recurrence of previously diagnosed MN has been reported after administration of inactivated SARS-CoV-2 vaccination 2 , and a case of minimal change disease after mRNA-1273 vaccination 3 . Exacerbation of the nephrotic syndrome following a second injection of an mRNA vaccine seems to suggest a role of these vaccines in triggering MN. Further studies are needed to elucidate the early post-vaccination immune response mechanism.

PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous Nephropathy

Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

No conflict of interest to declare for all authors